Deutsche Bank Aktiengesellschaft Reiterates “Hold” Rating for Oxford Biomedica (LON:OXB)

Oxford Biomedica (LON:OXB)‘s stock had its “hold” rating reaffirmed by Deutsche Bank Aktiengesellschaft in a research report issued on Wednesday, Digital Look reports. They currently have a GBX 595 price target on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s target price would suggest a potential upside of 36.63% from the stock’s previous close.

Other research analysts have also issued research reports about the company. Royal Bank Of Canada reduced their price target on Oxford Biomedica from GBX 1,140 to GBX 900 and set an “outperform” rating on the stock in a report on Monday, August 10th. Jefferies Financial Group reissued a “buy” rating and issued a GBX 8.27 price objective on shares of Oxford Biomedica in a report on Tuesday, June 2nd. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Oxford Biomedica has a consensus rating of “Moderate Buy” and an average price target of GBX 580.85.

Oxford Biomedica Stock Performance

Shares of Oxford Biomedica stock opened at GBX 435.49 on Wednesday. The business’s 50 day moving average price is GBX 566.92 and its 200 day moving average price is GBX 606.44. The company has a market cap of £527.10 million, a price-to-earnings ratio of -16.18 and a beta of 1.10. The company has a debt-to-equity ratio of 162.16, a quick ratio of 1.67 and a current ratio of 2.20. Oxford Biomedica has a one year low of GBX 427 and a one year high of GBX 952.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.